PLGA nanoparticles for oral delivery of prion-specific antigen: a novel approach to chronic wasting disease vaccination

1. Aguzzi, A., Nuvolone, M. & Zhu, C. The immunobiology of prion diseases. Nat. Publish Group. https://doi.org/10.1038/nri3553 (2013).

   Google Scholar 

2. Zerr, I. et al. Creutzfeldt–Jakob disease and other prion diseases. Nat. Reviews Disease Primers Vol. 10 (1), 1–16. https://doi.org/10.1038/s41572-024-00497-y (2024).

   Google Scholar 

3. Prusiner, S. B. Prion 1998 Prusiner. Proc. Natl. Acad. Sci. U S A. 95, 13363–13383. https://doi.org/10.1073/pnas.95.23.13363 (2025).

   Google Scholar 

4. Napper, S. & Schatzl, H. M. Vaccines for prion diseases: a realistic goal?. Springer science and business media deutschland GmbH. https://doi.org/10.1007/s00441-023-03749-7 (2023).

5. Napper, S. & Schatzl, H. M. Oral vaccination as a potential strategy to manage chronic wasting disease in wild Cervid populations. Front. Media S A https://doi.org/10.3389/fimmu.2023.1156451 (2023).

6. Taki, A. & Smooker, P. Small wonders—the use of nanoparticles for delivering antigen. MDPI AG. https://doi.org/10.3390/vaccines3030638 (2015).

7. Abdelaziz, D. H. et al. Immunization of cervidized Transgenic mice with multimeric deer prion protein induces self-antibodies that antagonize chronic wasting disease infectivity in vitro. https://doi.org/10.1038/s41598-017-11235-8

8. Abdelaziz, D. H. et al. Recombinant prion protein vaccination of Transgenic elk PrP mice and reindeer overcomes self-tolerance and protects mice against chronic wasting disease. J. Biol. Chem. 293 (51), 19812–19822. https://doi.org/10.1074/jbc.RA118.004810 (2018).

   Google Scholar 

9. Uskoković, V. Nanomedicine for the poor: A lost cause or an Idea whose time has yet to come? Future Med. Ltd. https://doi.org/10.2217/nnm-2021-0024 (2021).

   Google Scholar 

10. Cao, P., Xu, Z. P. & Li, L. Tailoring functional nanoparticles for oral vaccine delivery: recent advances and future perspectives. Compos. B Eng. 236, 109826. https://doi.org/10.1016/J.COMPOSITESB.2022.109826 (2022).

    Google Scholar 

11. Cai, K. et al. Dimeric drug polymeric nanoparticles with exceptionally high drug loading and quantitative loading efficiency. J. Am. Chem. Soc. 137 (10), 3458–3461. https://doi.org/10.1021/JA513034E (2015).

    Google Scholar 

12. Alsaab, H. O. et al. PLGA-based nanomedicine: History of advancement and development in clinical applications of multiple diseases. Pharmaceutics 14 (12), https://doi.org/10.3390/PHARMACEUTICS14122728 (2022).

13. des Rieux, A., Fievez, V., Garinot, M., Schneider, Y. J. & Préat, V. Nanoparticles as potential oral delivery systems of proteins and vaccines: A mechanistic approach. J. Controlled Release. 116 (1), 1–27. https://doi.org/10.1016/j.jconrel.2006.08.013 (2006).

    Google Scholar 

14. Lagreca, E. et al. Recent advances in the formulation of PLGA microparticles for controlled drug delivery. Prog. Biomater. 9 (4), 153–174 https://doi.org/10.1007/S40204-020-00139-Y (2020).

15. Ghitman, J., Biru, E. I., Stan, R. & Iovu, H. Review of hybrid PLGA nanoparticles: future of smart drug delivery and theranostics medicine. Mater. Des. 193, 108805. https://doi.org/10.1016/J.MATDES.2020.108805 (2020).

    Google Scholar 

16. Omidian, H., Wilson, R. L. & Castejon, A. M. Recent advances in Peptide-Loaded PLGA nanocarriers for drug delivery and regenerative medicine. Pharmaceuticals https://doi.org/10.3390/PH18010127 (2025).

17. Garinot, M. et al. PEGylated PLGA-based nanoparticles targeting M cells for oral vaccination. J. Controlled Release. 120 (3), 195–204. https://doi.org/10.1016/j.jconrel.2007.04.021 (2007).

    Google Scholar 

18. Ma, L. J. et al. Quantitative evaluation of cellular internalization of polymeric nanoparticles within laryngeal cancer cells and immune cells for enhanced drug delivery. Nanoscale Res. Lett. https://doi.org/10.1186/s11671-021-03498-y (2021).

    Google Scholar 

19. Cruz, K. P. et al. Development and characterization of PLGA nanoparticles containing 17-DMAG, an Hsp90 inhibitor. Front. Chem. 9, 644827 https://doi.org/10.3389/FCHEM.2021.644827/BIBTEX (2021).

20. Salvador, A. et al. Design and evaluation of surface and adjuvant modified PLGA microspheres for uptake by dendritic cells to improve vaccine responses. Int. J. Pharm. 496 (2), 371–381. https://doi.org/10.1016/j.ijpharm.2015.10.037 (2015).

    Google Scholar 

21. Sivadasan, D., Sultan, M. H., Madkhali, O., Almoshari, Y. & Thangavel, N. ‘Polymeric lipid hybrid nanoparticles (Plns) as emerging drug delivery platform—a comprehensive review of their properties, preparation methods, and therapeutic applications. Pharmaceutics https://doi.org/10.3390/PHARMACEUTICS13081291 (2021).

22. Xu, J. et al. Controllable microfluidic production of Drug-Loaded PLGA nanoparticles using partially water-miscible mixed solvent microdroplets as a precursor. Sci. Rep. 7 (1), 1–12 (2017).

    Google Scholar 

23. Hernández-Giottonini, K. Y. et al. ‘PLGA nanoparticle preparations by emulsification and nanoprecipitation techniques: effects of formulation parameters. Royal Soc. Chem. https://doi.org/10.1039/c9ra10857b (2020).

24. Anand, U., Lu, J., Loh, D., Aabdin, Z. & Mirsaidov, U. Hydration Layer-Mediated pairwise interaction of nanoparticles. Nano Lett. 16 (1), 786–790. https://doi.org/10.1021/ACS.NANOLETT.5B04808 (2016).

    Google Scholar 

25. Elsutohy, M. M., Selo, A., Chauhan, V. M., Tendler, S. J. B. & Aylott, J. W. Enhanced distance-dependent fluorescence quenching using size tuneable core shell silica nanoparticles. RSC Adv. 8, 62, 35840–35848 https://doi.org/10.1039/C8RA05929B (2018).

26. Kaiser-Schulz, G. et al. Polylactide-Coglycolide microspheres coencapsulating Recombinant tandem prion protein with CpG-Oligonucleotide break Self-Tolerance to prion protein in Wild-Type mice and induce CD4 and CD8 T cell responses. 1 https://www.jimmunol.org. (2007).

27. Gilch, S. et al. Chronic wasting disease. Top. Curr. Chem. 305, 51–78. https://doi.org/10.1007/128_2011_159 (2011).

    Google Scholar 

28. Dölen, Y. et al. PLGA nanoparticles Co-encapsulating NY-ESO-1 peptides and IMM60 induce robust CD8 and CD4 T cell and B cell responses. Front. Immunol. https://doi.org/10.3389/fimmu.2021.641703 (2021).

    Google Scholar 

29. Silva, A. L., Soema, P. C., Slütter, B., Ossendorp, F. & Jiskoot, W. ‘PLGA particulate delivery systems for subunit vaccines: linking particle properties to immunogenicity. https://doi.org/10.1080/21645515.2015.1117714 (Taylor and Francis inc., 2016).

30. Rajapaksa, T. E., Stover-Hamer, M., Fernandez, X., Eckelhoefer, H. A. & Lo, D. D. Claudin 4-targeted protein incorporated into PLGA nanoparticles can mediate M cell targeted delivery. J. Controlled Release 142 (2), 196–205. https://doi.org/10.1016/J.JCONREL.2009.10.033 (2010).

    Google Scholar 

31. Bachmann, M. F. & Jennings, G. T. Vaccine delivery: A matter of size, geometry. Kinet. Mol. Patterns https://doi.org/10.1038/nri2868 (2010).

32. Allahyari, M. et al. Co-delivery of PLGA nanoparticles loaded with rSAG1 antigen and TLR ligands: an 1 efficient vaccine against chronic toxoplasmosis 2 3’. https://www.elsevier.com/open-access/userlicense/1.0/ (2021).

33. Danhier, F. et al. PLGA-based nanoparticles: an overview of biomedical applications. J. Controlled Release. 161 (2), 505–522. https://doi.org/10.1016/j.jconrel.2012.01.043 (2012).

    Google Scholar 

34. Storni, T. et al. Nonmethylated CG motifs packaged into Virus-Like particles induce protective cytotoxic T cell responses in the absence of systemic side effects. J. Immunol. 172 (3), 1777–1785. https://doi.org/10.4049/jimmunol.172.3.1777 (2004).

    Google Scholar 

35. Ishii, K. J. & Akira, S. Toll or toll-free adjuvant path toward the optimal vaccine development. https://doi.org/10.1007/s10875-007-9087-x (2007).

36. Yang, J. et al. Recent applications of PLGA in drug delivery systems. Multidiscip. DigiT. Publish. Inst. (MDPI). https://doi.org/10.3390/polym16182606 (2024).

37. Guidelines on stability evaluation of vaccines. https://www.who.int/biologicals (2006).

38. Goñi, F. et al. Mucosal immunization with an attenuated Salmonella vaccine partially protects white-tailed deer from chronic wasting disease. Vaccine 33 (5), 726–733 https://doi.org/10.1016/j.vaccine.2014.11.035 (2015).

39. Church, J. A. et al. Predictors of oral rotavirus vaccine immunogenicity in rural Zimbabwean infants. Vaccine 38 (13), 2870 https://doi.org/10.1016/J.VACCINE.2020.01.097 (2020).

40. Patriarca, P. A., Wright, P. F. & John, T. J. Factors affecting the immunogenicity of oral poliovirus vaccine in developing countries: review. Rev. Infect. Dis. 13 (5), 926–939. https://doi.org/10.1093/CLINIDS/13.5.926 (1991).

    Google Scholar 

41. Neutra, M. R. & Kozlowski, P. A. Mucosal vaccines: The promise and the challenge. https://doi.org/10.1038/nri1777 (2006).

42. Gilch, S. et al. Polyclonal anti-PrP auto-antibodies induced with dimeric PrP interfere efficiently with PrPSc propagation in prion-infected cells. J. Biol. Chem. 278 (20), 18524–18531. https://doi.org/10.1074/jbc.M210723200 (2003).

    Google Scholar 

43. Ertmer, A. et al. The tyrosine kinase inhibitor STI571 induces cellular clearance of PrP Sc in prion-infected cells. J. Biol. Chem. 279 (40), 41918–41927. https://doi.org/10.1074/jbc.M405652200 (2004).

    Google Scholar 

Download references

Authors and Affiliations

1. Calgary Prion Research Unit, Faculty of Veterinary Medicine, University of Calgary, Calgary, Alberta, T2N 4Z6, Canada

   Mohamed M. Elsutohy, Dalia Abdelaziz, Chimoné S. Dalton, Byron Kruger, Shirley Phan, Yo-Ching Cheng, Kevin Low, Hanaa Ahmed-Hassan & Hermann M. Schätzl

2. Hotchkiss Brain Institute, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada

   Mohamed M. Elsutohy, Dalia Abdelaziz, Chimoné S. Dalton, Byron Kruger, Shirley Phan, Yo-Ching Cheng, Kevin Low, Hanaa Ahmed-Hassan & Hermann M. Schätzl

3. Snyder Institute for Chronic Diseases, University of Calgary, Calgary, Canada

   Mohamed M. Elsutohy, Dalia Abdelaziz, Chimoné S. Dalton, Byron Kruger, Shirley Phan, Yo-Ching Cheng, Kevin Low, Hanaa Ahmed-Hassan & Hermann M. Schätzl

4. Department of Biochemistry and Molecular Biology, Faculty of Pharmacy, Helwan University, Cairo, Egypt

   Dalia Abdelaziz

5. Zoonoses Department, Faculty of Veterinary Medicine, Cairo University, Giza, Egypt

   Hanaa Ahmed-Hassan

Contributions

ME, DA, CSD, HS designed the study and the experiments, ME performed the nanoparticles optimization and preparation, DA, CSD, YC, SP performed the bioassay, sample collection and processing. BK, performed the ELISpot assay, HH, KL prepared the protein used in the study.ME, DA, HS wrote the manuscript, HS supervised the whole study and obtained the fund supported the study. All the authors revised the manuscript.

Corresponding author

Correspondence to Hermann M. Schätzl.

Competing interests

The authors declare no competing interests.

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.

Reprints and permissions